OS

BackBox Introduces Zero Trust Network Operations (ZTNO) to Automate Zero Trust Security for Network Operations

Retrieved on: 
Wednesday, January 31, 2024
Policy, OS, BackBox, NetOps, Automation, CLI, ZTA, Privilege (evidence), API, Zero trust security model, NIST, Cryptocurrency

DALLAS, Jan. 31, 2024 /PRNewswire/ -- In a significant stride towards enhancing network security, BackBox, a leader in security-centric automation for network teams, today introduces Zero Trust Network Operations (ZTNO). This groundbreaking offering is a best practice framework with six actionable pillars to automate cybersecurity considerations at the network layer for NetOps teams. To simplify ZTNO for network teams, BackBox has enhanced its Network Automation Platform with improved Privileged Access Manager, Network Vulnerability Management, and Search.

Key Points: 
  • BackBox Automation Platform for Network Teams announces improved Privileged Access Manager, Network Vulnerability Manager, and Search to simplify Zero Trust for NetOps
    DALLAS, Jan. 31, 2024 /PRNewswire/ -- In a significant stride towards enhancing network security, BackBox , a leader in security-centric automation for network teams, today introduces Zero Trust Network Operations (ZTNO).
  • To simplify ZTNO for network teams, BackBox has enhanced its Network Automation Platform with improved Privileged Access Manager, Network Vulnerability Management, and Search.
  • "BackBox's introduction of Zero Trust Network Operations (ZTNO) marks a significant advancement in network security, aligning NetOps with Zero Trust principles in a user-friendly, efficient, and comprehensive manner," said BackBox CEO Andrew Kahl.
  • For more information on BackBox Zero Trust Network Operations, go to https://backbox.com/ztno .

NATIONAL CAR CHARGING AWARDED CONTRACT WITH THE STATE OF CALIFORNIA

Retrieved on: 
Tuesday, January 30, 2024
OS, California Department, DGS, Transport, NCC, RFP, Electricity

DENVER, Jan. 30, 2024 /PRNewswire/ -- The nation's largest and most experienced independent electric vehicle (EV) charging station reseller and installer, National Car Charging (NCC), announced today that they have been exclusively awarded a multi-year charging station procurement contract for non-networked DC fast charging infrastructure with the State of California through the California Department of General Services (DGS).

Key Points: 
  • DENVER, Jan. 30, 2024 /PRNewswire/ -- The nation's largest and most experienced independent electric vehicle (EV) charging station reseller and installer, National Car Charging (NCC), announced today that they have been exclusively awarded a multi-year charging station procurement contract for non-networked DC fast charging infrastructure with the State of California through the California Department of General Services (DGS).
  • "We're incredibly honored to be selected to support the State of California as they continue to electrify their fleets," shared Jim Burness , CEO and founder of National Car Charging.
  • The California Legislature recently appropriated general funds to DGS Office of Sustainability (OS) to support the installation of EV charging infrastructure.
  • Through DGS' rigorous RFP process, National Car Charging was selected to be the exclusive non-networked DC fast charging provider for the state.

Launch by NTT DATA Announces Innovation Operating System

Retrieved on: 
Monday, January 22, 2024
Culture, Organization, NTT DATA, NTT, Engineering, OS, Communication, Growth, Mobile phone

Today’s enterprises have a choice: innovate -- or stagnate and lose market share. According to NTT DATA’s Innovation Index, 96% of participants said innovation is a primary source of growth for their enterprise. Yet only 21% of those surveyed say they are meeting innovation goals. Enterprises need a way to establish a culture and operating system for excelling at continuous innovation.

Key Points: 
  • PLANO, Texas, Jan. 22, 2024 (GLOBE NEWSWIRE) -- NTT DATA , a global digital business and IT services and its branded capability focused on accelerated digital experience design and engineering, Launch by NTT DATA , have unveiled a new Innovation Operating System (OS).
  • “Innovation OS is a distillation of what companies need to become trailblazers – to become great at invention,” said Tammy Soares, President, Launch by NTT DATA.
  • According to NTT DATA’s Innovation Index , 96% of participants said innovation is a primary source of growth for their enterprise.
  • Companies from energy to automotive have turned to Launch by NTT DATA to help design, build, optimize, and launch initiatives.

Merck’s KEYTRUDA® (pembrolizumab) Reduced the Risk of Death by 38% Versus Placebo as Adjuvant Therapy for Patients With Renal Cell Carcinoma (RCC) at an Increased Risk of Recurrence Following Nephrectomy

Retrieved on: 
Saturday, January 27, 2024
Research, FDA, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, MSD, Dana–Farber Cancer Institute, Renal cell carcinoma, Death, VEGF, Patient, M1, OS, RCC, Harvard Medical School, ASCO, Survival, DFS, Medicine, Society, NED, Cancer, Nephrectomy, Kidney, Risk, Recurrence, Disease, Safety, Eisai, Merck & Co., CPS, Rated R, MRK, Pharmaceutical industry

At 48 months, the estimated OS rate was 91.2% for patients who received KEYTRUDA compared to 86.0% for patients who received placebo.

Key Points: 
  • At 48 months, the estimated OS rate was 91.2% for patients who received KEYTRUDA compared to 86.0% for patients who received placebo.
  • Treatment-related adverse events (TRAEs) occurred in 79.1% of patients (n=386) in the KEYTRUDA arm and 53.0% of patients (n=263) in the placebo arm.
  • Grade 3-4 TRAEs occurred in 18.6% of patients in the KEYTRUDA arm and 1.2% of patients in the placebo arm.
  • Treatment-related adverse events resulting in discontinuation of any treatment occurred in 18.2% of patients in the KEYTRUDA arm and 0.8% of patients in the placebo arm.

Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Disease-Free Survival (DFS) as Adjuvant Therapy Versus Observation in High-Risk Patients With Localized Muscle-Invasive and Locally Advanced Urothelial Carcinoma After Surgery

Retrieved on: 
Friday, January 26, 2024
Biotechnology, FDA, Diabetes, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Science, Clinical Trials, MSD, Development, Death, Patient, OS, Carcinoma, Bladder cancer, ASCO, DFS, Society, NCI, Cancer, ClinicalTrials.gov, Risk, PD-L1, Recurrence, Disease, National Cancer Institute, Safety, Merck & Co., Observation, Pembrolizumab, Rated R, Bangladesh Technical Education Board, MRK, Pharmaceutical industry

Median DFS was 29.0 months (95% CI, 21.8-not evaluable [NE]) for KEYTRUDA and 14.0 months (95% CI, 9.7-20.20) for observation, an improvement of 15 months.

Key Points: 
  • Median DFS was 29.0 months (95% CI, 21.8-not evaluable [NE]) for KEYTRUDA and 14.0 months (95% CI, 9.7-20.20) for observation, an improvement of 15 months.
  • AMBASSADOR (A031501)/KEYNOTE-123 is a randomized, open-label Phase 3 trial (ClinicalTrials.gov, NCT03244384 ) evaluating KEYTRUDA versus observation for the adjuvant treatment of patients with localized MIUC and locally advanced resectable urothelial carcinoma.
  • 17.4% of patients receiving KEYTRUDA withdrew from the trial without event versus 27.2% from the observation arm.
  • Grade ≥3 adverse events occurred in 48.4% of patients receiving KEYTRUDA versus 31.8% of patients under observation.

VodafoneZiggo and BlueConic Win Platinum Award for Best Customer Data Platform Solution

Retrieved on: 
Thursday, January 25, 2024
Technology, Data Management, Telecommunications, CDP, Probability, OS, VodafoneZiggo, B2B, Churn, Acquisition, CRM, Sales

Working with market-leading customer data platform (CDP) BlueConic , Dutch telecommunications company VodafoneZiggo has revolutionised its customer engagement strategies, resulting in a 17.6% increase in website interactions and a 4.53% reduction in churn.

Key Points: 
  • Working with market-leading customer data platform (CDP) BlueConic , Dutch telecommunications company VodafoneZiggo has revolutionised its customer engagement strategies, resulting in a 17.6% increase in website interactions and a 4.53% reduction in churn.
  • The collaboration has earned both companies a Platinum award for Best Customer Data Platform Solution in Juniper Research’s Future Digital Awards for Telco Innovation.
  • While some CDPs mostly focus on data unification and others tout personalization offerings, VodafoneZiggo is able to do both with BlueConic.
  • We’re delighted their success with our customer data platform has been recognized by the esteemed analysts at Juniper Research.”

Exelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024

Retrieved on: 
Thursday, January 25, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Exelixis, Huntsman Cancer Institute, Patient, Prostate cancer, PST, Progression-free survival, NHT, OS, ASCO, Survival, Clinical research, University, Society, Metastasis, RECIST, PFS, BIRC, ITT

The detailed findings are being presented during Oral Abstract Session A: Prostate Cancer at 7:55 a.m. PST on January 25 at the American Society of Clinical Oncology 2024 Genitourinary Cancers Symposium (ASCO GU).

Key Points: 
  • The detailed findings are being presented during Oral Abstract Session A: Prostate Cancer at 7:55 a.m. PST on January 25 at the American Society of Clinical Oncology 2024 Genitourinary Cancers Symposium (ASCO GU).
  • The PFS analysis was conducted in the first 400 randomized patients in the intent-to-treat (PFS ITT) population and per protocol.
  • While a trend toward OS improvement was observed, the data were immature and did not meet the threshold for statistical significance.
  • The PFS benefit and the trend for an OS benefit were observed across subgroups of high-risk populations, as presented in Table 1.

Announcing the New MLPerf Client Working Group

Retrieved on: 
Wednesday, January 24, 2024
Technology, Semiconductor, Consulting, Other Technology, Professional Services, Software, Networks, Hardware, Data Management, Artificial Intelligence, Engineering, Silicon, Learning, Deep learning processor, OS, Microsoft, Arm, Software development, AI, Benchmarking, GM, Dell Technologies, Safety, AMD, Acceleration, Qualcomm, Creativity, Intel, Jaladi Raja Rao, Machine learning, Asus, Sales

Today MLCommons® is announcing the formation of a new MLPerf™ Client working group.

Key Points: 
  • Today MLCommons® is announcing the formation of a new MLPerf™ Client working group.
  • Initial MLPerf Client working group participants include representatives from AMD, Arm, ASUSTeK, Dell Technologies, Intel, Lenovo, Microsoft, NVIDIA, and Qualcomm Technologies, Inc. among others.
  • “Large language models are a natural and exciting starting point for our MLPerf Client working group.
  • For more information on the MLPerf Client working group, including information on how to join and contribute to the benchmarks, please visit the working group page or contact the chairs via email at [email protected] .

Multiple New Analyses Reinforce the Role of BAVENCIO® (avelumab) First-Line Maintenance as a Standard of Care in Patients with Locally Advanced or Metastatic Urothelial Carcinoma

Retrieved on: 
Monday, January 22, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, FDA, Clinical Trials, Senior, Roger Hawkins (drummer), Tamas, Patient, Carcinoma, MD, Merck Group, ADC, OS, Health care, UC, Bladder cancer, Brentuximab vedotin, ASCO, CUP, Survival, Society, READY, Quality of life, Experiment (probability theory), Safety, PRO, Merck Serono, Toxicity, Doctor of Philosophy, BMI, Merck, BSC, Czech, Pharmaceutical industry

Data include real-world studies that confirm median overall survival (OS) of approximately 30 months in patients without progression after first-line chemotherapy.

Key Points: 
  • Data include real-world studies that confirm median overall survival (OS) of approximately 30 months in patients without progression after first-line chemotherapy.
  • These and other analyses will be presented at the 2024 American Society of Clinical Oncology’s annual Genitourinary Cancers Symposium, January 25-27, in San Francisco.
  • “Avelumab in the first-line maintenance setting is a standard of care for patients with locally advanced or metastatic bladder cancer, with a well-established efficacy and safety profile and supported by years of real-world experience.
  • READY CUP Italy Real-World Study: The prospective, noninterventional compassionate use program (CUP) provided Italian patients with locally advanced or metastatic UC early access to BAVENCIO first-line maintenance before reimbursement.

Eight-Year Data for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Continue to Demonstrate Longest Survival Benefit vs. Sunitinib Reported in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

Retrieved on: 
Monday, January 22, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Bristol Myers Squibb, Death, Checkmate, Patient, Progression-free survival, OS, RCC, ASCO, Survival, Nivolumab, Ipilimumab, IRRC, Society, Risk, Immunotherapy, MD Anderson Cancer Center, Division, PFS, Abstract, Safety, Confidence interval, University, BMY, Sunitinib, IMDC, ITT

Patients treated with Opdivo plus Yervoy maintained superior survival and more durable response benefits compared to those who received sunitinib in both patients with intermediate- and poor-risk prognostic factors and across all randomized patients.

Key Points: 
  • Patients treated with Opdivo plus Yervoy maintained superior survival and more durable response benefits compared to those who received sunitinib in both patients with intermediate- and poor-risk prognostic factors and across all randomized patients.
  • DOR: Median DOR was 82.8 months for patients treated with Opdivo plus Yervoy compared to 19.8 months with sunitinib.
  • ORR: ORR benefits were maintained with Opdivo plus Yervoy compared to sunitinib (42% vs. 27%).
  • DOR: For patients treated with Opdivo plus Yervoy, median DOR was 76.2 months compared to 25.1 months with sunitinib.